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Effect of Metformin Versus Diet and Exercise on Ovulation & Menstrual Regularity in PCOS 
Nasim Karim,  Khalid Mustafa, Talea Hoor,  Riffat Farooqui  
 
ABSTRACT:  
Objective: To compare the effects of metformin with diet & exercise on  ovulation & menstrual regularity in PCOS infertile women . 
Study Design:  Randomized clinical trial.  
Place & Duration of study:  Private hospital infertility clinic at Karachi from 2001-2004.  
Patients & Methods: One hundred & eleven PCOS women with primary infertility were enrolled. and divided into group A & B with 57 & 54 patients 
respectively. Group A received tablet metformin 500mg thrice daily along with diet & exercise advice while group B was kept on diet & exercise alone 
(30-60 minutes walk daily & avoidance of oily foods, red meat & bakery products) for a period of 90 days. Menstrual regularity & plasma progesterone 
level were evaluated at day-0 and day-90. Fasting serum glucose, insulin, follicle stimulating hormone, luteinizing hormone, prolactin, testosterone & 
ultrasound pelvis were done at day- 0 for diagnosis of PCOS.  
Results: 100 patients completed the study. 50 patients in each group.In group A, 44 (88%) patients developed regular cycles with statistically significant 
increase in serum progesterone whereas in group B only 3(6%) patients developed regular cycles with non-significant increase in serum progesterone level 
from day-0 to day-90. Group A showed ovulation in 82% patients in comparison to Group B where ovulation occurred in only 6%  of patients. 
Conclusion: Metformin  produced beneficial effects in comparison to diet & exercise alone in PCOS infertile women. 
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INTRODUCTION 
Polycystic ovarian syndrome (PCOS) is a prevalent 
disorder that affects approximately 6-10% of women of 
child bearing age.1,2Insulin resistance and 
hyperinsulinemia appears to play an important 
pathogenic role in both obese and lean women with 
PCOS.3,4,5 These women are at increased risk for type II 
diabetes, dyslipidemia, hypertension & atherosclerosis 
due to associated insulin resistance.6,7,8It is characterized 
by chronic anovulation with either oligomennorhea or 
amenorrhoea & hyperandrogenism.PCOS is the most 
common cause of anovulatory infertility.9 There is ample 
evidence that hyperinsulinemia results in increased 
ovarian androgen biosynthesis in vivo and in vitro and 
decreased sex hormone binding globulin (SHBG) 
synthesis from the liver, leading to increased 
bioavailability of free androgens 10. This excess in local 
ovarian androgen production augmented by 
hyperinsulinemia causes premature follicular atresia and 
anovulation 11 
Hyperinsulinemia may have a direct effect on the 
hypothalamus and/or pituitary to increase serum 
luteinizing hormone (LH) concentrations and therefore 
indirectly increasing LH-dependent ovarian androgen 
biosynthesis possibly resulting in abnormal LH and 
follicle stimulating hormone (FSH) release and 
subsequent oligomenorrhoea. Hyperinsulinemia may also 
directly affect the folliculogenesis and may arrest growth 
of antral follicles after they have reached a diameter 
between 5 and 8 mm.In PCOS serum concentration of 
estradiol lie within the normal ranges for the early 
follicular and midfollicular phases of the cycle12 but the 
pattern of secretion differs from that in the normal 
menstrual cycle because there is no pre-ovulatory or 
midluteal increase in estradiol concentrations. The action 
of estradiol on the hypothalamic pituitary axis and on the 
endometrium is unopposed because of a lack of cyclical 
progesterone secretion 13. 
 A pathophysiologically rationalized therapeutic 
approach should take into account the fact that 
reproductive and cardiometabolic abnormalities coexist 
in PCOS14. Metformin have been introduced as a 
pharmaceutical option targeting not only insulin 
resistance (IR), but several other aspects of the syndrome 
including reproductive abnormalities.15 It decreases 
hyperstimulation & cycle cancellations.16It appears to 
affect the ovarian function in a dual mode, through the 
alleviation of insulin excess acting upon the ovary & 
through direct ovarian effects. This later effect directly 
stimulates several steroidogenic enzymes in the ovary 
like 17α hydroxylase/ 17, 20- lyase and 3β-
hydroxysteroid dehydrogenase, P450 side chain cleavage 
and StAR protein.17Insulin action on steroidogenesis at 
the ovary is presumed despite the co-existance of 
peripheral insulin resistance.18 Lifestyle intervensions 
focusing predominantly on diet & physical exercise is 
considered the first line treatment for metabolic 
complications in overweight & obese women with PCOS 
& may have the potential to improve ovulatory 
function.19 Shedding even a modest amount of weight 
may help.Loosing less than 10% of initial body weight 
has been shown to cut high levels of body fats and blood 
sugar. Weight loss also improves insulin resistance.20 
Thus insulin resistance & associated compensatory 
hyperinsulinemia play a central role in the pathogenesis 
of PCOS. 21 
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With this background present study was designed to 
evaluate the effect of metformin in comparison to diet & 
exercise on ovulation & menstrual regularity in patients 
having polycystic ovarian syndrome. 
SUBJECTS AND METHODS 
The clinical trial was carried out from 2001-2004 in 
which 111 women were selected from an infertility clinic 
of a private hospital at Karachi. Eligibility criteria 
included women of reproductive age group with ages 
between 20-40 years having primary infertility, 
oligomenorrhoea, obesity, hirsutism, fasting 
hyperinsulinemia (>10µU/ml) and fasting serum sugar 
level < 6.1mmol/L as ≥ 6.1mmol/L is WHO diabetic 
criteria, 2000.Consent was taken from each study 
participant before they were enrolled in the 
study.Preliminary data, date of follow up visit & 
laboratory investigations were recorded on a specially 
designed proforma. The patients were divided into two 
groups A & B randomly.Even number of proformas for 
group A (57 patients) metformin treated group & odd 
number of proformas for group B (54 patients) diet & 
exercise treated group.Tablet metformin HCl (escalation 
dose) was started at 500mg once daily per orally for one 
week & was increased to thrice daily for a period of 
3months. The initial week was excluded from the 
study.Group B patients were advised for exercise (30-60 
minutes walk daily) & change in diet pattern (avoidance 
of oily foods, red meat & bakery products). Menstrual 
cyclical changes were noted & serum progesterone was 
evaluated at day-0 & day-90 of the study as an indicator 
of ovulation (progesterone cut off value for ovulation 
was ≥ 4ng/ml). 
Analytical method: Analysis for the serum progesterone 
was performed on automated random access 
immunoassay analysis “Immulite” from Diagnostic 
Product Corporation (DPC) by using commercial kits 
supplied by DPC.   
Statistical Analysis: The observations were recorded on 
day 0 and day 90 for menstrual cyclical changes and 
serum progesterone (P). Statistical evaluation was done 
by using student (paired) t-test utilizing SPSS Version 10 
 
RESULTS 
A total of 100 patients completed the study period with 
50 patients in each group. All patients presented in the 
infertility clinic with complain of no issue that is they 
had primary infertility.  In group A out of 50 patients 35 
(70%) had oligomenorrhoea & 15 (30%) had irregular 
cycles. In group B out of 50 patients 41 (82%) had 
oligomenorrhoea & 9 (18%) had irregular cycles (Table 
1). 
Physiological, metabolic, endocrinologic parameters 
along with clinical features & ultrasound pelvis were 
done for making diagnosis of PCOS in Group A and B 
(Table 2a, 2b) 
In group A following 90 days of treatment with 
metformin 33 (66%) patients out of 35(70%) developed 
regular cycles, while 2 (4%) patients had no change.  Out 
of 15 (30%) patients who had irregular cycles at day-0, 
 11 (22%) patients showed regularity in their cycles at 
day-90 while 4 (8%) patients had no change in their 
menstrual cyclicity. In group B after 90 days of diet & 
exercise treatment 39 (78%) patients out of 41(82%) had 
no change, while 2 (4%) patients developed regular 
cycles. Out of 9 (18%) patients with irregular cycles only 
1(2%) patient showed regularity in cycles. (Table3). 
In group A serum progesterone level showed an increase 
from a mean ±SD of 1.3±0.3ng/ml to 9.5±5.1ng/ml from 
day-0 to day-90. On statistical evaluation it was found to 
be significant with P-value of 0.001. In group B serum 
progesterone level showed an increase from a mean ±SD 
of 1.6±0.6 to 1.74±1.1ng/ml from day-0 to day-90. On 
statistical evaluation it was found to be non-significant 
with P-value of 0.067 (Table 4). 
All patients (100%) showed increase in their 
progesterone level in group A but in group B 32(64%) 
patients showed increase, 17 (34%) patients had a 
decrease & 1(2%) had no change in the serum 
progesterone level (Table 5). 
This increase in serum progesterone was divided into 2 
groups (a) < 4 ng/ml and b) > 4 ng/ml.  In group A 9 
(18%) patients had an increase which was < 4 ng/ml 
while 41 (82%) patients had an increase which was > 4 
ng/ml. This latter value was taken consistent with 
ovulation. In group B 48 (96%) patients had serum 
progesterone level < 4 ng/ml while 2 (6.25%) patients 
had an increase in level which was > 4 ng/ml. This latter 
value was taken consistent with ovulation  (Table 6). 
 
DISCUSSION 
The etiology of PCOS remain obscure & the variability 
in phenotype expression continues to render the clinical 
care & research concerning this heterogenous condition 
challenging.22In women with PCOS the ovary does not 
make the hormones needed for the eggs to fully mature. 
Follicles may start to grow and build up fluid but none of 
the follicle becomes large enough. Instead some follicles 
may remain as cysts. Since no follicle becomes large 
enough and no egg matures or is released, ovulation does 
not occur and the hormone progesterone is not made. 
Without progesterone, a woman’s menstrual cycle 
becomes irregular or ceases. In addition the cysts so 
produced make male hormones, which also prevent 
ovulation in thse women23. 
In group-A the metformin treated group 35 (70%) 
patients had oligomenorrhoea and 15 (30%) had irregular 
cycles and anovulation as confirmed by their low serum 
progesterone levels (mean±SD of 1.3±0.3 ng/ml).  In 
group A 33 (66%) patients developed regular cycles after 
3 months of metformin therapy while 11 (22%) patients 
who previously had irregular cycles experienced 
improvement in menstrual flow & had regular cycles. 
Remaining 6 patients did not had any change. Out of 
these 44 patients, 41 (82%) ovulated as confirmed by 
their serum progesterone level > 4 ng/ml. Velazquez 24  
has reported the results of 22 women with PCOS 
completing 6 months of metformin therapy 500 mg three 





PRESENTING CHARACTERISTICS OF PATIENTS 
(n=100) 
S.NO SYMPTOMS NO. OF PATIENTS Group A % 
NO. OF PATIENTS 
Group B % 
1. No issue (infertility) 50 100 50 100 
2. Oligomenorrhoea 35 70 41 82 
3. Irregular cycles 15 30 9 18 





TABLE  2a 
BASELINE DIAGNOSTIC CHARACTERISTICS OF PATIENTS 
 
S.NO.    CHARACTERISTICS 








  Group B 
 A: Physiological  
1.  Weight (Kg) 45.0-102 69.4±11.8 52.4-92.5 75.4±8.8 
2.  Height (m) 1.4-1.7 1.6±0.1 1.4-1.7 1.6±0.1 
3.  BMI (Kg/m2) 16.7-39.2 27.5±4.8 20.7-41.7 30.0±4.8 
 B: Metabolic 
4.  Fasting serum glucose mg/dl) 65-110 92.74±13 75-110 92.00±11.1 
5.  Fasting serum insulin (ul/ml) 10.4-51 20.6±11 10.2-30.4 18.8±5.0 
 C: Endocrine 
6.  Serum  progesterone(ng/ml) 0.6-1.9 1.3±0.3 0.7-3.0 1.6±0.6 
7.  Serum FSH (ng/ml) 0.3-32.5 4.2±5.8 0.5-16.1 4.8±3.1 
8.  Serum LH (ng/ml) 1.8-105.5 16.6±17.9 3.4-41.0 16.1±7.4 
9.  Serum prolactin (ng/ml) 3.7-34.8 12.4-6.8 5.0-27.2 12.0-4.8 
10.  Serum testosterone (ng/ml) 0.7-4.9 3.0±0.8 1.3-4.9 3.1±0.7 






BASELINE CHARACTERISTICS OF PATIENTS 
 (n=100) 
 
S.NO. CHARACTERISTICS GROUP A (n=50) 
GROUP B 
(n=50) 
  NO. OF 
PATIENTS 
% NO. OF 
PATIENTS 
% 
1. Acanthosis nigricans 04 8 03 6 
2. Male type baldness 05 10 03 6 
3. Acne 13 26 17 34 
4. Hirsutism (face, arms & legs) 33 66 39 78 
5. Ultrasound pelvis 














(50) S.NO. CYCLICAL PATTERN DAY-0 CHANGES DAY-90 DAY-0 CHANGES DAY-90 
Regular 
cycles 
33 (66%) Regular 
cycles 
2        
(4%) 1. Oligomenorrhoea 
 
35      
(70%) No change 2      
(4%) 
 
41       
(82%) No change 39 (78%) 
Regular 
cycles 
11 (22%) Regular 
cycles 
1 (2%) 
2. Irregular cycles 
15   
(30%) 
No change 4      
(8%) 
9        
(18%) 





SERUM PROGESTERONE FROM DAY-0 TO DAY-90 
(n=100) 
 
GROUPS CHARACTERISTICS DAY-0 MEAN±SD 
DAY-90 
MEAN±SD P VALUE 
A Serum progesterone (ng/ml) 1.3±0.3 9.5±5.1 0.001* 
B Serum progesterone (ng/ml) 1.6±0.6 1.74±1.1 0.067 
 





CHANGE IN SERUM PROGESTERONE AT DAY-90 
(n=100) 
 
Group Decrease in serum progesterone 
Increase in serum 
progesterone 
No change in serum 
progesterone 
 No. % No. % No. % 
A          
(50) 0 0 50 100 0 0 
B          






TABLE  6 
INCREASE IN SERUM PROGESTERONE FROM DAY-0 TO DAY-90 
(n=100) 
 
Groups Parameter Sub-Groups 
Change in 
level Day-0 Day-90 
A <4 ng/ml 50 (100%) 9 (18%)    A 
(50) 
Serum progesterone (ng/ml) 
B > 4 ng/ml 0 41 (82%) 
A <4 ng/ml 50(100%) 48 (96%) 
   B 
(50) 
Serum progesterone (ng/ml) 
B > 4 ng/ml 0 2(6.25) 
 
oligomenorrhoea or amenorrhoea, hirsutism and 
polycystic ovaries as assessed by ultrasound at baseline.  
Kolodziejczyk25 and Vandermolen26 have documented 
that metformin administered at a dose of 500 mg three 
times daily increased menstrual cyclicity and improved 
spontaneous ovulation. These findings are coinciding 
with our results whereas Acbay27 and Ehrmann28 have 
failed to demonstrate salutary effect of metformin in 
PCOS. In the later study the mean body mass index of 
the women approached 40 kg/m2 and metformin is said to 
be  ineffective in cases of morbid obesity. 
We have observed a significant increase in the serum 
progesterone level from 1.3±0.3 to 9.5±5.1 ng/ml. All 
patients treated with metformin showed an increase with 
41 (82%) patients an incline > 4 ng/ml (considered 
consistent with ovulation) while 9 (18%) patients 
showing an increase in the serum progesterone from 
baseline but < 4 ng/ml (considered inconsistent with 
ovulation). Vandermolen26 used the serum progesterone 
level ≥ 4 ng/ml to determine whether participants had 
ovulated or not. We have also taken the same cut-off 
value. Velazquez24 reported ovulation in 13 out of 15 
patients with an ovulation percentage of 86.7%. All 13 
patients had regular menses and serum progesterone 
values in the ovulatory range (3.1-28 ng/ml). Fleming29 
have found 37 out of 45 patients ovulating that is 82% 
ovulation rate. This is in complete accordance to our 
study.  Jakubowicz30 have observed a significant increase 
in the serum progesterone level from 70.3±5.4 to 
123.7±12.4 pmol/L in 26 PCOS patients after 4 weeks of 
metformin therapy. All these are coinciding with our 
study. In contrast to this Nestler31 has observed a 
decrease in the serum progesterone level from 3.1±0.3 to 
2.2±0.2 mmol/L at the end of 4-6 weeks of metformin 
therapy. He included 31 PCOS women all having normal 
weight or thin built with BMI between 18 to 23.7 Kg/ m2 
whereas mean BMI in our patients was 27.5 Kg/m2. 
 In group-B out of 50 patients 41(82%) had 
oligomenorrhoea while 9(18%)  had irregular cycles. 
After 12 weeks of diet & exercise in the former group 
39(78%) patients did not had any change while 2(4%) 
developed regular cycles. Whereas in the latter group 
with irregular cycles only 1(2%) developed menstrual 
cycle regularity. Moghetti et al.32 has observed in 23 
caucasian women with PCOS oligomenorrhoea in 20 
(86.95%) patients & irregular cycles in 3(13%) patients 
which is coinciding with us. Kiddy et al.33found among 
24 PCOS women that 11 patients lost less than 5% of 
their body weight & only 1(12.5%) had regularity over a 
7 months period with strict low calorie diet.In our study 
mean weight reduction was 1.1 Kg & only 3(6%) showed 
menstrual regularity after 3 months of diet restriction & 
exercise regularly. Hutchison34 has reported a reduction 
of 1.6 kg in mean body weight of PCOS kept on exercise 
& diet restriction which is more or less the same as our 
finding. However Nestler 35 has reported a non-
significant increase in serum progesterone level of 12 
PCOS women given placebo for 4-6 weeks. Out of 26 
women only 1(4%) patient ovulated spontaneously.We 
have also found non-significant increase in the 
progesterone level of 50 women kept on diet control & 




Metformin has produced beneficial effects on the 
reproductive function in comparison to diet & exercise 
alone in PCOS infertile women. It produced cyclical 
regularity in 88% of cases with an ovulation rate of 82% 
in comparison to diet & exercise treated group where 
menstrual regularity occured in 6%  of cases with an  
ovulation rate of 6%.  However conception rate & the 
live birth rate could not be ascertained in these females 
due to financial constraints.  
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